BILL ANALYSIS                                                                                                                                                                                                    �



                                                                  SB 1053
                                                                  Page  1

          Date of Hearing:   August 6, 2014

                        ASSEMBLY COMMITTEE ON APPROPRIATIONS
                                  Mike Gatto, Chair

                   SB 1053 (Mitchell) - As Amended:  July 2, 2014 

          Policy Committee:                             HealthVote:12-6

          Urgency:     No                   State Mandated Local Program:  
          Yes    Reimbursable:              No

           SUMMARY  

          Effective January 1, 2016, this bill requires most health plans  
          and insurers to cover all FDA-approved contraceptive drugs,  
          devices, and products for women, as well as related counseling  
          and follow-up services and voluntary sterilization procedures.  

          This bill also prohibits cost-sharing, restrictions, or delays  
          in the provision of covered services, but allows cost-sharing  
          for non-preferred contraceptives if the generic or preferred  
          equivalents are offered with no cost sharing.

           FISCAL EFFECT  

          1)According to the California Health Benefits Review Program  
            (CHBRP), annual fiscal impact in the private insurance market  
            as follows:

             a)   $65 million in increased premiums for private health  
               care coverage statewide, including: 

                  i)        $37 million in premium costs to private  
                    employers.
                 ii) $26 million in premium costs to individuals.
                 iii) $2 million in premium costs to CalPERS.

             a)   $216 million in cost savings due to averted deliveries  
               and abortion services.  Assuming these costs savings are  
               proportionate to increased expenditures:

                  i)        $123 million in savings to private employers.
                  ii)       $86 million in savings to individuals.
                  iii)      $7 million in savings to CalPERS.








                                                                  SB 1053
                                                                  Page  2


            In the private market, estimated savings from averted  
            pregnancies outweigh costs by a factor of 3.  However, there  
            is a time lag in the first year where savings from averted  
            deliveries are only accrued after the expected gestational  
            period of nine months.

          1)Estimated Medi-Cal managed care costs of $10 million (10%  
            GF/90% federal), and projected cost savings of $56 million  
            (about 45% GF/55% federal) annually after implementation due  
            to an estimated 6,000 additional pregnancies averted.  

            Because the state pays only 10% of the costs for family  
            planning services but pays a much higher percentage of the  
            costs for labor and delivery, as well as children's health  
            care services, it is estimated the fiscal impact of this bill  
            on Medi-Cal is net positive, and that GF savings outweigh GF  
            costs by a significant factor.  

          2)Estimated potential increased state costs exceeding $5 million  
            to pay the costs of this contraceptive coverage on behalf of  
            enrollees in Covered California, if this mandate is determined  
            to exceed the state's essential health benefits (EHBs)  
            requirements.  Federal regulations hold the state responsible  
            for paying costs of additional mandated benefits. Providing  
            more contraceptives would also likely lead to averted costs  
            for delivery and abortion services as described above, but it  
            does not appear this could offset state costs.  It is possible  
            that this contraception mandate could be considered  
            cost-neutral by plans, which would avoid the potential state  
            cost liability, but it is far from certain that this would  
            occur. Federal regulations related to EHBs are discussed in  
            more detail below.

          3)CHBRP notes there is a possibility the estimates provided  
            could underestimate the costs, because they were not able to  
            capture the impact of removing utilization controls for plans  
            currently using them in the administration of their  
            contraceptive coverage. Since these protocols are used on a  
            case by case basis and their utilization varies by health  
            plan, it is difficult to capture their impact at a statewide  
            level. In addition, CHBRP notes, it is unclear how prevalent  
            such controls may still be if this bill were law.  The  
            estimates provided are the marginal cost and savings of  
            covering all FDA-approved contraceptives, and do not reflect  








                                                                 SB 1053
                                                                  Page  3

            changes in cost and utilization based on modifying utilization  
            controls.  To the extent this broader mandate increases  
            utilization of higher-cost methods without leading to a higher  
            number of pregnancies averted, it could increase costs beyond  
            what is noted above.

          4)Costs to the Department of Managed Health Care of $300,000 to  
            verify compliance and clarify coverage requirements via  
            regulation (Managed Care Fund).  Ongoing costs should be  
            minor, in the range of $50,000 annually (Managed Care Fund).

          5)Minor ongoing costs to California Department of Insurance to  
            oversee compliance, in the range of $50,000 annually  
            (Insurance Fund).

          6)Reduced future cost pressure to state and local governments in  
            a variety of health, social services, and education programs,  
            including Medi-Cal, due to reduced demand for these services  
            as a result of over 25,000 fewer unintended pregnancies  
            statewide. About half of pregnancies end in delivery.  These  
            cost savings are beyond the scope of this analysis but will be  
            cumulative and are likely to be significant.

           COMMENTS  

           1)Purpose  . The author states this bill builds on current state  
            and federal contraception mandates by requiring coverage of  
            each FDA-approved drug, device, and product. According to the  
            author, different interpretations of federal guidance have led  
            to a patchwork of contraceptive coverage policies, some of  
            which create barriers to particular methods.  The author  
            believes this bill furthers the intent of federal  
            contraceptive requirements and enhances reproductive autonomy.

           2)This bill expands upon existing contraceptive mandates  .   
            Existing state law requires group and individual health plans  
            to cover a variety of FDA-approved prescription contraceptive  
            methods designated by the plan, if the plan or policy provides  
            coverage for outpatient prescription drug benefits.

            The federal Patient Protection and Affordable Care Act (ACA)  
            mandates most plans cover a number of preventive health care  
            benefits, including (by reference to federal Health Resources  
            and Services Administration (HRSA) guidelines for women's  
            preventive health care), coverage of "all FDA-approved  








                                                                  SB 1053
                                                                  Page  4

            contraceptive methods, as approved by a physician."   
            Contraceptive  methods,  defined through guidance, include  
            barrier (condoms), hormonal (pills, ring, patch, injection),  
            emergency contraception (brand names Plan B, ella), implanted  
            devices (including intrauterine devices (IUDs) with or without  
            hormones), and permanent (sterilization).  Within each method,  
            there may be numerous products or types.  The most common  
            method, hormonal, includes several distinct delivery devices  
            that render the types quite different from each other, even  
            though they all work similarly from a clinical perspective.   
            For example, some women may be more adherent to the ring  
            versus the pill; other women may not be able to tolerate the  
            ring but prefer a quarterly injection.  Different types within  
            the same method also have differing effectiveness-women  
            receiving injections for birth control have fewer pregnancies  
            than women using the pill or the ring.  A Centers for Medicare  
            and Medicaid Services (CMS) FAQ document also clarifies health  
            plan issuers may use reasonable medical management techniques  
            to control costs and promote efficient delivery of care.

           3)Current Coverage  .  Given current legal mandates and demand for  
            coverage, there appears to be broad coverage of all  
            contraceptive methods in current practice.  However, actual  
            coverage of a specific drug or product can be quite nuanced.   
            For example, although federal guidance requires coverage of  
            all contraceptive methods, a plan may not cover all types or  
            all formulations within the method.

            Thus, even though a plan covers a range of methods and  
            complies with the letter of state and federal law, a woman may  
            encounter barriers to her preferred contraceptive method,  
            including step therapy (where a woman must try a lower-cost or  
            safer alternative before receiving what was originally  
            requested), a requirement for prior authorization before a  
            contraceptive is covered, or other acceptable medical  
            management techniques.  For example, if a woman requests the  
            ring, it appears a plan does not have to provide the ring with  
            no cost-sharing if they make an alternative hormonal method  
            available, such as the pill.  Federal guidance requires a plan  
            to accommodate any individual for whom a certain drug would be  
            medically inappropriate, as determined by the individual's  
            health care provider, and to cover a medically appropriate  
            alternative with no cost-sharing.  However, this rule is also  
            subject to interpretation.









                                                                  SB 1053
                                                                  Page  5

            Advocates who support this bill voice concern that medical  
            management techniques that limit or delay a woman's access to  
            her preferred method lead to lapsed or inconsistent  
            contraceptive use and increase risk of unintended pregnancy.   
            This bill attempts to address this by requiring coverage for  
            every FDA-approved drug, device, and product.
                
            4)Coverage in Medi-Cal  .  Medi-Cal covers a full range of  
            contraceptive services.  Contraception benefits in Medi-Cal  
            are reimbursed at a 90% federal matching rate.  However, there  
            are some limitations, and allowable medical management  
            techniques, similar to those that exist in the private market.  
             

           5)State Costs Associated with Mandates Exceeding Essential  
            Health Benefits  . The ACA requires individual and small-group  
            health plans to cover certain categories of benefits, called  
            Essential Health Benefits (EHBs). The ACA further specifies  
            that if states require plans in the Exchange to offer  
            additional benefits that go beyond the defined EHBs, then  
            states must pay the additional cost related to those mandates  
            for individuals in qualified health plans offered through an  
            Exchange, either to the individuals or to health plans on  
            behalf of individuals, excluding mandates enacted prior to  
            December 31, 2011.  A federal final rule on EHBs also  
            specifies that Exchanges must identify which state-required  
            benefits are in excess of EHBs for purposes of payment, and  
            that qualified health plan issuers must quantify the cost  
            attributable to each additional required benefit.  The rule  
            does not specify a federal enforcement mechanism. 

           6)Opposition  .  Health plans and insurers oppose this measure,  
            citing concern that it interferes and micromanages formularies  
            by preventing plans from imposing different cost-sharing  
            levels and imposing restrictions or delays.  They indicate a  
            desire to retain control over their prescription drug coverage  
            design and to retain the right to impose reasonable cost  
            management techniques in order to keep health care affordable.  
            In addition, Catholic health care facilities oppose this bill,  
            stating it exceeds federal requirements and does not conform  
            to the federal definition of religious employer.


           Analysis Prepared by  :    Lisa Murawski / APPR. / (916) 319-2081 









                                                                  SB 1053
                                                                  Page  6